US Food and Drug Administration (FDA)-approved diagnostic assays play an increasingly common role in managing patients to prolong lifespan while also enhancing quality of life. Diagnostic assays can be essential for the safe and effective use of therapeutics (companion diagnostic), or may inform on improving the benefit/risk ratio without restricting drug access (complementary diagnostic). This tutorial reviews strategic considerations for drug and assay development resulting in FDA-approved companion or complementary diagnostic status.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5355969 | PMC |
| http://dx.doi.org/10.1111/cts.12455 | DOI Listing |
Publication Analysis
Top Keywords
companion complementary
8
strategic considerations
8
diagnostic assays
8
complementary diagnostic
8
diagnostic
5
current status
4
status companion
4
complementary diagnostics
4
diagnostics strategic
4
considerations development
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!